Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study

Abstract

Tailored patient education improved the medication adherence of patients with chronic myeloid leukaemia. Without this, adherence behaviour tended to decline. Personal communication with a nurse proved to be an essential part of adherence support and should not be ignored.

Needs for information and reasons for (non)adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines

“…Other quantitative studies using a questionnaire found percentages of nonadherent CML patients ranging from 0% to 47%. 11,12,19,23,30,[34][35][36][37][38][39][40][41] Differences in the extent of nonadherence in studies are a well-known phenomenon in adherence research and relate to the drug, follow-up period and differences in measurement and calculation of adherence. 9,42 In the present study, a self-composed question was used to measure nonadherence ("How often do you not take your CML medicine?").…”

“…9,42 In the present study, a self-composed question was used to measure nonadherence ("How often do you not take your CML medicine?"). In the other studies, 11,12,19,23,30,[34][35][36][37][38][39][40][41] alternative questionnaires were used to measure medication adherence. Although the differences in measurements make it difficult to compare the results of studies, it is clear that a considerable number of CML patients have difficulties with adhering to their medication regimen.…”

“…Adequate provision of information has been positively related to medication adherence in CML. 11,19,23,28,30,34,37 To fulfil patients' needs for information, HCPs should provide information in a structured way and adapted to the possibilities of the individual patient to understand information and encourage patients to ask questions.…”

“…20,21,[26][27][28] In addition, to support patients to adhere to their medication, adequate information and communication is essential. 9,21,23,29,30 Despite the considerable attention medication adherence has received in recent years, the provision of information remains insufficient. 31 Care may be improved by meeting it to the CML patients' needs for information and communication.…”

Nilotinib activates endothelial TLR4 to exacerbate atherosclerosis

“…Nilotinib was approved by FDA as first and only CML therapy with Treatment-free Remission data in its label in 2017. Though nilotinib has achieved good tolerability and high potency, the emerging vascular adverse effects have limited its use as front-line therapy for CML (5)(6)(7)(8)(9). Here, we aimed to investigate the cellular mechanisms involved and to identify a therapeutic strategy to alleviate nilotinib-exacerbated atherosclerosis.…”